RetinAI Medical
<p>Ikerian AG (formerly RetinAI Medical AG) is a fast-growing digital healthcare company headquartered in Bern, Switzerland, focused on developing healthcare solutions to generate and organise insights and knowledge, enhance clinical diagnostics and pharmaceutical R&D. Improving patient outcomes and quality of life through innovation and working together with colleagues who love what they do is what gets us up every morning.</p><p>Both idealistic and pragmatic, we are passionate and execution-driven entrepreneurs who are striving to make an impact. In our daily work, we love to tackle challenges, value collaboration and speed in execution and create an environment where no day is the same.</p>
RetinAI Medical
<p>Ikerian AG (formerly RetinAI Medical AG) is a fast-growing digital healthcare company headquartered in Bern, Switzerland, focused on developing healthcare solutions to generate and organise insights and knowledge, enhance clinical diagnostics and pharmaceutical R&D. Improving patient outcomes and quality of life through innovation and working together with colleagues who love what they do is what gets us up every morning.</p><p>Both idealistic and pragmatic, we are passionate and execution-driven entrepreneurs who are striving to make an impact. In our daily work, we love to tackle challenges, value collaboration and speed in execution and create an environment where no day is the same.</p>
TL;DR
Founded: December 2016 (Bern, Switzerland)
Headquarters: Bern, Switzerland (with U.S. presence in Boston, MA)
Flagship product: RetinAI Discovery — image & data management platform for ophthalmology (FDA-cleared 510(k) and CE-marked)
Funding highlights: Pre-Series A CHF 2.3M (2019); Series A Extension USD 6.18M (May 2024); Series B first close USD 8M (Oct 2024); company reported USD 11.66M raised across Seed/Series A/Extension as of May 2024
Exit / M&A: Acquired by EssilorLuxottica (announced 15 Oct 2025)
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |
Company Overview
Problem Domain
Ophthalmology (retinal imaging, clinical workflows, research and pharmaceutical RWE analysis).
Founded
2016
Industry
Digital health / Medical software (Ophthalmology)
Funding Track Record
CHF 2.3M
Participation from Investiere and selected private investors
USD 6.18M (CHF 5.65M)
Company reported total of USD 11.66M raised across Seed, Series A and Series A Extension as of this date; Zürcher Kantonalbank participated in a first close in 2023
USD 8M (CHF 6.73M)
Participation from existing investors
Investor Signal
“Investor base includes strategic corporate investors and European VCs: Sanoptis (Series B lead), THINC Ventures (Topcon Healthcare CVC), Zürcher Kantonalbank (ZKB), Verve Ventures, btov Partners, Investiere, and other private investors; company was acquired by EssilorLuxottica (announced 15 Oct 2025).”